CoChat
Sign Up
Cited by 399Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Komoroski, B, Vachharajani, N, Feng, Y, Li, L, Kornhauser, D, Pfister, M·2009·Clinical Pharmacology & Therapeutics
DOI 10.1038/clpt.2008.250
Open this paper in CoChat — free account

Abstract

Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose from urine into the blood. This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. Significant reductions in fasting serum glucose (FSG) were observed on day 2 with 100 mg dapagliflozin (-9.3%, P < 0.001), and dose-dependent reductions were observed on day 13 with the 5-mg (-11.7%; P < 0.05), 25-mg (-13.3%; P < 0.05), and 100-mg (-21.8%; P < 0.0001) doses as compared with placebo. Significant improvements in oral glucose tolerance test (OGTT) were observed with all doses on days 2 and 13 (P < 0.001 as compared with placebo). On day 14, urine glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and 100-mg doses (as compared with no change for placebo), which were slightly lower than those on day 1. This was attributed to the decrease in filtered glucose load following improved glycemic control. Dapagliflozin produced dose-dependent increases in glucosuria and clinically meaningful changes in glycemic parameters in T2DM patients.

Overview

Integrity signals

Registry

Crossref · 10.1038/clpt.2008.250

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 3

  1. Chen J, 2008, Diabetes, 57, A682
  2. Oemar B.S, 1987, Clin. Nephrol, 27, 156
  3. Gibb D, 1995, NZ Med. J, 108, 252

Cited by

Sorted by citations

Items 301–399 of 399

Related

See all

Metadata

Authors
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M.
Affiliations
Bristol-Myers Squibb (United States) (US)
Corresponding author
Pfister, M
ORCID
Pfister, M
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2009-01-07
Volume
85
Issue
5
Pages
513-519
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
DOI
10.1038/clpt.2008.250
OpenAlex
W2000047428
Cited by
396
References
20
Citations by year
2026: 14 · 2025: 13 · 2024: 16 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 14 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 18 · 2014: 39 · 2013: 39 · 2012: 32
FWCI
27.68
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, glycosuria, fasting serum glucose, oral glucose tolerance test, dose-dependent effects, urinary glucose excretion
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucose Tolerance Test, Glucosides, Glycosuria, Humans, Hypoglycemic Agents, Male, Middle Aged, Time Factors, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review